Short Interest in Rein Therapeutics Inc. (NASDAQ:RNTX) Increases By 25.5%

Rein Therapeutics Inc. (NASDAQ:RNTX) saw a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 441,027 shares, a growth of 25.5% from the January 15th total of 351,493 shares. Currently, 1.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 140,201 shares, the days-to-cover ratio is presently 3.1 days. Based on an average daily trading volume, of 140,201 shares, the days-to-cover ratio is presently 3.1 days. Currently, 1.8% of the shares of the stock are short sold.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on RNTX shares. Wall Street Zen cut shares of Rein Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, December 14th. Brookline Capital Acquisition lowered shares of Rein Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. Citigroup cut Rein Therapeutics to a “hold” rating in a research note on Wednesday, January 21st. Loop Capital set a $6.00 target price on Rein Therapeutics in a research note on Monday, November 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Rein Therapeutics in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $8.00.

Rein Therapeutics Trading Up 2.7%

RNTX stock opened at $1.15 on Wednesday. The stock has a market capitalization of $30.23 million, a price-to-earnings ratio of -0.44 and a beta of 1.48. The firm’s 50-day moving average price is $1.27 and its two-hundred day moving average price is $1.29. Rein Therapeutics has a 12-month low of $1.02 and a 12-month high of $2.96.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Gleason Group Inc. bought a new stake in shares of Rein Therapeutics in the 3rd quarter worth approximately $26,000. Blair William & Co. IL bought a new stake in Rein Therapeutics in the second quarter valued at $33,000. Meridian Wealth Advisors LLC purchased a new position in Rein Therapeutics during the 2nd quarter valued at $40,000. Exencial Wealth Advisors LLC purchased a new position in Rein Therapeutics during the 2nd quarter valued at $43,000. Finally, Susquehanna International Group LLP bought a new position in Rein Therapeutics in the 3rd quarter worth $35,000. Institutional investors own 90.89% of the company’s stock.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.